1. Home
  2. NEHCW vs TCBP Comparison

NEHCW vs TCBP Comparison

Compare NEHCW & TCBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NEHCW
  • TCBP
  • Stock Information
  • Founded
  • NEHCW N/A
  • TCBP 2013
  • Country
  • NEHCW United States
  • TCBP United Kingdom
  • Employees
  • NEHCW N/A
  • TCBP N/A
  • Industry
  • NEHCW Oil & Gas Production
  • TCBP Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • NEHCW Energy
  • TCBP Health Care
  • Exchange
  • NEHCW Nasdaq
  • TCBP Nasdaq
  • Market Cap
  • NEHCW 836.3K
  • TCBP 831.0K
  • IPO Year
  • NEHCW N/A
  • TCBP 2022
  • Fundamental
  • Price
  • NEHCW $0.17
  • TCBP $1.69
  • Analyst Decision
  • NEHCW
  • TCBP Strong Buy
  • Analyst Count
  • NEHCW 0
  • TCBP 1
  • Target Price
  • NEHCW N/A
  • TCBP $48.00
  • AVG Volume (30 Days)
  • NEHCW 59.3K
  • TCBP 632.6K
  • Earning Date
  • NEHCW 05-14-2025
  • TCBP 11-25-2024
  • Dividend Yield
  • NEHCW N/A
  • TCBP N/A
  • EPS Growth
  • NEHCW 161.37
  • TCBP N/A
  • EPS
  • NEHCW 0.10
  • TCBP N/A
  • Revenue
  • NEHCW $626,103.00
  • TCBP N/A
  • Revenue This Year
  • NEHCW N/A
  • TCBP N/A
  • Revenue Next Year
  • NEHCW N/A
  • TCBP N/A
  • P/E Ratio
  • NEHCW $50.96
  • TCBP N/A
  • Revenue Growth
  • NEHCW N/A
  • TCBP N/A
  • 52 Week Low
  • NEHCW $0.14
  • TCBP $1.43
  • 52 Week High
  • NEHCW $0.70
  • TCBP $523.20
  • Technical
  • Relative Strength Index (RSI)
  • NEHCW N/A
  • TCBP 28.01
  • Support Level
  • NEHCW N/A
  • TCBP $1.43
  • Resistance Level
  • NEHCW N/A
  • TCBP $2.19
  • Average True Range (ATR)
  • NEHCW 0.00
  • TCBP 0.28
  • MACD
  • NEHCW 0.00
  • TCBP 0.19
  • Stochastic Oscillator
  • NEHCW 0.00
  • TCBP 20.57

About TCBP TC BioPharm (Holdings) plc

TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.

Share on Social Networks: